Smart missile drug takes aim at Hard-to-Treat colorectal cancer

NCT ID NCT07693751

First seen Jul 09, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This trial tests a new medicine called SOT109 for people with advanced colorectal cancer that cannot be removed by surgery or has spread. SOT109 is designed to find and attack cancer cells that have a specific marker (CDH17) while sparing healthy cells. The study has two parts: the first finds safe dose levels, and the second compares two doses to see which works best at shrinking tumors. Participants must be at least 18 years old and in relatively good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SOT109 (a targeted antibody-drug that delivers a chemotherapy payload to cancer cells carrying the CDH17 marker)
What this could lead to
If successful, this could provide a new treatment option for people with advanced colorectal cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial, so the drug may not shrink tumors or may cause significant side effects. It is too soon to know if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (LOCALLY ADVANCED OR METASTATIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arensia Exploratory Medicine Research Unit, Institute of Oncology

    Chisinau, Moldova

    Contact Phone: •••-•••-••••

  • NEXT Houston

    Houston, Texas, 77054, United States

    Contact Phone: •••-•••-••••

  • NEXT Virginia

    Faifax, Virginia, 22031, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.